Literature DB >> 33398095

The Rcs stress response inversely controls surface and CRISPR-Cas adaptive immunity to discriminate plasmids and phages.

Leah M Smith1, Simon A Jackson1,2, Lucia M Malone1, James E Ussher1, Paul P Gardner2,3,4, Peter C Fineran5,6,7.   

Abstract

Bacteria harbour multiple innate defences and adaptive CRISPR-Cas systems that provide immunity against bacteriophages and mobile genetic elements. Although some bacteria modulate defences in response to population density, stress and metabolic state, a lack of high-throughput methods to systematically reveal regulators has hampered efforts to understand when and how immune strategies are deployed. We developed a robust approach called SorTn-seq, which combines saturation transposon mutagenesis, fluorescence-activated cell sorting and deep sequencing to characterize regulatory networks controlling CRISPR-Cas immunity in Serratia sp. ATCC 39006. We applied our technology to assess csm gene expression for ~300,000 mutants and uncovered multiple pathways regulating type III-A CRISPR-Cas expression. Mutation of igaA or mdoG activated the Rcs outer-membrane stress response, eliciting cell-surface-based innate immunity against diverse phages via the transcriptional regulators RcsB and RcsA. Activation of this Rcs phosphorelay concomitantly attenuated adaptive immunity by three distinct type I and III CRISPR-Cas systems. Rcs-mediated repression of CRISPR-Cas defence enabled increased acquisition and retention of plasmids. Dual downregulation of cell-surface receptors and adaptive immunity in response to stress by the Rcs pathway enables protection from phage infection without preventing the uptake of plasmids that may harbour beneficial traits.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33398095     DOI: 10.1038/s41564-020-00822-7

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  77 in total

1.  The drug-resistant bacteria that pose the greatest health threats.

Authors:  Cassandra Willyard
Journal:  Nature       Date:  2017-02-28       Impact factor: 49.962

2.  A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.

Authors:  Migle Kazlauskiene; Georgij Kostiuk; Česlovas Venclovas; Gintautas Tamulaitis; Virginijus Siksnys
Journal:  Science       Date:  2017-06-29       Impact factor: 47.728

Review 3.  Type III CRISPR-Cas Immunity: Major Differences Brushed Aside.

Authors:  Gintautas Tamulaitis; Česlovas Venclovas; Virginijus Siksnys
Journal:  Trends Microbiol       Date:  2016-10-20       Impact factor: 17.079

4.  Bioinformatic evidence of widespread priming in type I and II CRISPR-Cas systems.

Authors:  Thomas J Nicholson; Simon A Jackson; Bradley I Croft; Raymond H J Staals; Peter C Fineran; Chris M Brown
Journal:  RNA Biol       Date:  2018-09-18       Impact factor: 4.652

Review 5.  The Biology of CRISPR-Cas: Backward and Forward.

Authors:  Frank Hille; Hagen Richter; Shi Pey Wong; Majda Bratovič; Sarah Ressel; Emmanuelle Charpentier
Journal:  Cell       Date:  2018-03-08       Impact factor: 41.582

6.  Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.

Authors:  Ole Niewoehner; Carmela Garcia-Doval; Jakob T Rostøl; Christian Berk; Frank Schwede; Laurent Bigler; Jonathan Hall; Luciano A Marraffini; Martin Jinek
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

Review 7.  The pan-immune system of bacteria: antiviral defence as a community resource.

Authors:  Aude Bernheim; Rotem Sorek
Journal:  Nat Rev Microbiol       Date:  2019-11-06       Impact factor: 60.633

8.  A novel interference mechanism by a type IIIB CRISPR-Cmr module in Sulfolobus.

Authors:  Ling Deng; Roger A Garrett; Shiraz A Shah; Xu Peng; Qunxin She
Journal:  Mol Microbiol       Date:  2013-02-03       Impact factor: 3.501

Review 9.  The arms race between bacteria and their phage foes.

Authors:  Hannah G Hampton; Bridget N J Watson; Peter C Fineran
Journal:  Nature       Date:  2020-01-15       Impact factor: 49.962

10.  Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.

Authors:  Joshua R Elmore; Nolan F Sheppard; Nancy Ramia; Trace Deighan; Hong Li; Rebecca M Terns; Michael P Terns
Journal:  Genes Dev       Date:  2016-02-04       Impact factor: 11.361

View more
  6 in total

Review 1.  SorTn-seq: a high-throughput functional genomics approach to discovering regulators of bacterial gene expression.

Authors:  Leah M Smith; Simon A Jackson; Paul P Gardner; Peter C Fineran
Journal:  Nat Protoc       Date:  2021-08-04       Impact factor: 13.491

2.  Structural basis for broad anti-phage immunity by DISARM.

Authors:  Jack P K Bravo; Cristian Aparicio-Maldonado; Franklin L Nobrega; Stan J J Brouns; David W Taylor
Journal:  Nat Commun       Date:  2022-05-27       Impact factor: 17.694

3.  High viral abundance and low diversity are associated with increased CRISPR-Cas prevalence across microbial ecosystems.

Authors:  Sean Meaden; Ambarish Biswas; Ksenia Arkhipova; Sergio E Morales; Bas E Dutilh; Edze R Westra; Peter C Fineran
Journal:  Curr Biol       Date:  2021-11-09       Impact factor: 10.834

4.  Type I CRISPR-Cas provides robust immunity but incomplete attenuation of phage-induced cellular stress.

Authors:  Lucia M Malone; Hannah G Hampton; Xochitl C Morgan; Peter C Fineran
Journal:  Nucleic Acids Res       Date:  2022-01-11       Impact factor: 16.971

5.  A histidine kinase and a response regulator provide phage resistance to Marinomonas mediterranea via CRISPR-Cas regulation.

Authors:  Patricia Lucas-Elío; Luisa Raquel Molina-Quintero; Hengyi Xu; Antonio Sánchez-Amat
Journal:  Sci Rep       Date:  2021-10-18       Impact factor: 4.379

6.  Antibiotics Used in Empiric Treatment of Ocular Infections Trigger the Bacterial Rcs Stress Response System Independent of Antibiotic Susceptibility.

Authors:  Nathaniel S Harshaw; Nicholas A Stella; Kara M Lehner; Eric G Romanowski; Regis P Kowalski; Robert M Q Shanks
Journal:  Antibiotics (Basel)       Date:  2021-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.